The effect of probiotic supplementation on performance, inflammatory markers and gastro-intestinal symptoms in elite road cyclists

Elite athletes may suffer from impaired immune function and gastro-intestinal (GI) symptoms, which may affect their health and may impede their performance. These symptoms may be reduced by multi-strain probiotic supplementation. Therefore, the aim of the current study is to examine the effects of p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the International Society of Sports Nutrition 2021-05, Vol.18 (1), p.36-36
Hauptverfasser: Schreiber, Chen, Tamir, Snait, Golan, Ron, Weinstein, Ayelet, Weinstein, Yitzhak
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Elite athletes may suffer from impaired immune function and gastro-intestinal (GI) symptoms, which may affect their health and may impede their performance. These symptoms may be reduced by multi-strain probiotic supplementation. Therefore, the aim of the current study is to examine the effects of probiotic supplementation on aerobic fitness characteristics, inflammatory markers and incidence and severity of GI symptoms in elite cyclists. Twenty-seven male cyclists, ranked elite or category 1 level competitions, were randomly assigned to a multi-strain probiotic-supplemented group (E, n = 11) or placebo group (C, n = 16). All participants visited the laboratory at the beginning of the study and following 90 d of supplementation/placebo. Prior to testing, all participants completed a GI symptoms questionnaire and underwent physical and medical examination, and anthropometric measurements. Venous blood was drawn for inflammatory markers analysis. The cyclists then underwent maximal oxygen consumption (VO max) test and time-to-fatigue (TTF) test at 85 % of maximal power, 3 h following the VO max test. All testing procedures were repeated after 90 d of probiotic / placebo treatment (double blind design). Lower incidence of nausea, belching, and vomiting (P 
ISSN:1550-2783
1550-2783
DOI:10.1186/s12970-021-00432-6